Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Adaptive Biotechnologies says FDA issues EUA for T-Detect COVID » 18:47
03/05/21
03/05
18:47
03/05/21
18:47
ADPT

Adaptive Biotechnologies

$42.20 /

-1.3999 (-3.21%)

, MSFT

Microsoft

$231.58 /

+4.72 (+2.08%)

Adaptive Biotechnologies…

Adaptive Biotechnologies (ADPT) announced that the U.S. FDA issued an Emergency Use Authorization for T-Detect COVID to confirm recent or prior COVID-19 infection. This first-in-class T cell- based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft (MSFT).

ShowHide Related Items >><<
MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

ADPT Adaptive Biotechnologies
$42.20 /

-1.3999 (-3.21%)

ADPT Adaptive Biotechnologies
$42.20 /

-1.3999 (-3.21%)

03/03/21
Fly Intel: Top five analyst downgrades
03/03/21 Goldman Sachs
Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
12/17/20 BTIG
BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

03/05/21 Morgan Stanley
Microsoft price target raised to $290 from $285 at Morgan Stanley
03/03/21 Citi
Microsoft assumed with a Buy at Citi
02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

ADPT Adaptive Biotechnologies
$42.20 /

-1.3999 (-3.21%)

  • 16
    Jul
MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

ADPT Adaptive Biotechnologies
$42.20 /

-1.3999 (-3.21%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

Periodicals
30K U.S. groups hacked via Microsoft email software flaws, KrebsOnSecurity says » 17:07
03/05/21
03/05
17:07
03/05/21
17:07
MSFT

Microsoft

$231.58 /

+4.72 (+2.08%)

, SWI

SolarWinds

$16.13 /

+0.11 (+0.69%)

No fewer than 30,000…

No fewer than 30,000 organizations across the U.S., including a large number of small businesses, towns, cities, and local governments, have in the past few days been hacked by an aggressive Chinese cyber espionage unit centered on stealing email from victim organizations, KrebsOnSecurity reports, citing multiple sources. The espionage unit is exploiting four newly-found flaws in Microsoft (MSFT) Exchange Server email software, and has seeded hundreds of thousands of victim organizations globally with tools that give hackers total remote control over impacted systems, the report says. Such recent hacks may well end up far eclipsing the damage done by the SolarWinds (SWI) hacks, the report notes. Reference Link

ShowHide Related Items >><<
SWI SolarWinds
$16.13 /

+0.11 (+0.69%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

03/05/21 Morgan Stanley
Microsoft price target raised to $290 from $285 at Morgan Stanley
03/03/21 Citi
Microsoft assumed with a Buy at Citi
02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
SWI SolarWinds
$16.13 /

+0.11 (+0.69%)

03/03/21 Citi
SolarWinds assumed with a Buy at Citi
02/23/21 Truist
Palo Alto Networks price target raised to $425 from $385 at Truist
02/22/21 JMP Securities
Pure Storage price target raised to $35 from $26 at JMP Securities
02/22/21 JMP Securities
Crowdstrike price target raised to $295 from $180 at JMP Securities
SWI SolarWinds
$16.13 /

+0.11 (+0.69%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

SWI SolarWinds
$16.13 /

+0.11 (+0.69%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

SWI SolarWinds
$16.13 /

+0.11 (+0.69%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

MSFT Microsoft
$231.58 /

+4.72 (+2.08%)

Hot Stocks
EMA says bamlanivimab can be considered as monotherapy treatment for COVID-19 » 11:16
03/05/21
03/05
11:16
03/05/21
11:16
LLY

Eli Lilly

$203.63 /

+3.06 (+1.53%)

The EMA's human…

The EMA's human medicines committee, or CHMP, has completed its review on the use of Eli Lilly's monoclonal antibodies bamlanivimab and etesevimab to treat patients with COVID-19, announced the EMA. "The Agency concluded that bamlanivimab and etesevimab can be used together to treat confirmed COVID-19 in patients who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe. The Agency also looked at the use of bamlanivimab alone and concluded that, despite uncertainties around the benefits of monotherapy, it can be considered a treatment option," the EMA announced. Reference Link

ShowHide Related Items >><<
LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

LLY Eli Lilly
$203.63 /

+3.06 (+1.53%)

Periodicals
Take-Two CEO says players 'ready for $70 games,' VGC reports » 11:12
03/05/21
03/05
11:12
03/05/21
11:12
TTWO

Take-Two

$170.42 /

-3.03 (-1.75%)

, MSFT

Microsoft

$227.70 /

+0.84 (+0.37%)

, SNE

Sony

$102.24 /

+0.39 (+0.38%)

Take-Two (TTWO) CEO…

Take-Two (TTWO) CEO Strauss Zelnick reiterated his company's view that the move to charge $70 instead of $60 for the Xbox Series X (MSFT) and PlayStation 5 (SNE) versions of "NBA 2K21" was the right one, since the public was "ready" for the price hike, VGC's Chris Scullion reports, citing comments from the Morgan Stanley Technology, Media & Telecom Conference. "We announced a $70 price point for NBA 2K21, our view was that we're offering an array of extraordinary experiences, lots of replayability, and the last time there was a frontline price increase in the US was 2005, 2006, so we think consumers were ready for it," Zelnick said. The CEO did not seem to suggest, though, that all future games will cost $70 going forwards, instead saying the company needs to focus on providing a level of content that justifies that price point, the author notes. Reference Link

ShowHide Related Items >><<
TTWO Take-Two
$170.42 /

-3.03 (-1.75%)

SNE Sony
$102.24 /

+0.39 (+0.38%)

MSFT Microsoft
$227.70 /

+0.84 (+0.37%)

TTWO Take-Two
$170.42 /

-3.03 (-1.75%)

02/09/21 Wells Fargo
Take-Two price target raised to $235 from $205 at Wells Fargo
02/09/21 Wedbush
Take-Two price target raised to $226 from $210 at Wedbush
02/09/21 Cowen
Take-Two price target raised to $229 from $213 at Cowen
02/09/21 Credit Suisse
Take-Two price target raised to $204 from $199 at Credit Suisse
MSFT Microsoft
$227.70 /

+0.84 (+0.37%)

03/05/21 Morgan Stanley
Microsoft price target raised to $290 from $285 at Morgan Stanley
03/03/21 Citi
Microsoft assumed with a Buy at Citi
02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
SNE Sony
$102.24 /

+0.39 (+0.38%)

01/12/21 Citi
Sony PS5 sales to date 'steady but somewhat disappointing,' says Citi
12/16/20 Benchmark
Chicken Soup for the Soul price target raised to $25 from $20 at Benchmark
12/16/20 Craig-Hallum
Chicken Soup for the Soul price target raised to $30 from $25 at Craig-Hallum
10/19/20 Credit Suisse
Corsair Gaming initiated with an Outperform at Credit Suisse
TTWO Take-Two
$170.42 /

-3.03 (-1.75%)

SNE Sony
$102.24 /

+0.39 (+0.38%)

MSFT Microsoft
$227.70 /

+0.84 (+0.37%)

TTWO Take-Two
$170.42 /

-3.03 (-1.75%)

SNE Sony
$102.24 /

+0.39 (+0.38%)

MSFT Microsoft
$227.70 /

+0.84 (+0.37%)

TTWO Take-Two
$170.42 /

-3.03 (-1.75%)

SNE Sony
$102.24 /

+0.39 (+0.38%)

MSFT Microsoft
$227.70 /

+0.84 (+0.37%)

TTWO Take-Two
$170.42 /

-3.03 (-1.75%)

SNE Sony
$102.24 /

+0.39 (+0.38%)

MSFT Microsoft
$227.70 /

+0.84 (+0.37%)

Recommendations
Microsoft price target raised to $290 from $285 at Morgan Stanley » 07:19
03/05/21
03/05
07:19
03/05/21
07:19
MSFT

Microsoft

$226.81 /

-0.81 (-0.36%)

Morgan Stanley analyst…

Morgan Stanley analyst Keith Weiss raised the firm's price target on Microsoft to $290 from $285 and keeps an Overweight rating on the shares, arguing that Microsoft is well positioned to gain an even larger share of the IT wallet, particularly as Cloud adoption picks up in larger enterprises. However, unlike a "breadth of well secularly positioned stocks in software," Microsoft's valuation "remains very attractive," setting up an attractive buying opportunity, Weiss tells investors.

ShowHide Related Items >><<
MSFT Microsoft
$226.81 /

-0.81 (-0.36%)

MSFT Microsoft
$226.81 /

-0.81 (-0.36%)

03/03/21 Citi
Microsoft assumed with a Buy at Citi
02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
MSFT Microsoft
$226.81 /

-0.81 (-0.36%)

MSFT Microsoft
$226.81 /

-0.81 (-0.36%)

MSFT Microsoft
$226.81 /

-0.81 (-0.36%)

MSFT Microsoft
$226.81 /

-0.81 (-0.36%)

Hot Stocks
Eli Lilly research and development group publishes pirtobrutinib trial data » 06:48
03/05/21
03/05
06:48
03/05/21
06:48
LLY

Eli Lilly

$200.53 /

-1.42 (-0.70%)

Loxo Oncology at Lilly, a…

Loxo Oncology at Lilly, a research and development group of Eli Lilly, announced that The Lancet has published data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in relapsed or refractory chronic lymphocytic leukemia, or CLL, small lymphocytic lymphoma, or SLL, mantle cell lymphoma, or MCL and other non-Hodgkin's lymphomas. Pirtobrutinib is an investigational, highly selective, non-covalent Bruton's tyrosine kinase, or BTK, inhibitor. The data in the publication include key findings previously presented at the 2020 American Society of Hematology. The publication includes safety and efficacy data for 323 relapsed or refractory patients that were enrolled to the BRUIN Phase 1/2 trial as of September 27, 2020.

ShowHide Related Items >><<
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:55
03/05/21
03/05
04:55
03/05/21
04:55
LLY

Eli Lilly

$200.53 /

-1.42 (-0.70%)

Analysts discuss Eli…

Analysts discuss Eli Lilly's Alzheimer's Disease Drug, Donanemab and the real-world clnical implications with Paul R. Solomon, PhD on an Analyst/Industry conference call to be held on March 5.

ShowHide Related Items >><<
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

LLY Eli Lilly
$200.53 /

-1.42 (-0.70%)

Thursday
Earnings
Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) » 16:13
03/04/21
03/04
16:13
03/04/21
16:13
RPTX

Repare Therapeutics

$27.36 /

-4.31 (-13.61%)

, BMY

Bristol-Myers

$59.25 /

-1.5 (-2.47%)

Cash and cash…

Cash and cash equivalents, restricted cash and marketable securities as of December 31, 2020 were $333.9M. "We met or exceeded key business and program milestones in 2020. In the first half, we secured more than $300 million in new balance sheet capital from our IPO and from the up-front payments associated with our Bristol Myers Squibb collaboration, all of which we believe will accelerate program progress. In the second half, we continued to execute on our strategic goals by successfully launching our Phase 1/2 clinical trial for RP-3500, which is currently enrolling patients. 10 sites have been activated across North America and Europe," said Lloyd M. Segal, CEO. "We continue to advance our discovery platform and have now designated our second clinical program, RP-6306, for which we have initiated IND-enabling studies."

ShowHide Related Items >><<
BMY Bristol-Myers
$59.25 /

-1.5 (-2.47%)

RPTX Repare Therapeutics
$27.36 /

-4.31 (-13.61%)

03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
12/29/20 Northland
Northland ups Repare Therapeutics price target to $42, calls a Top Pick for 2021
10/28/20
Fly Intel: Top five analyst initiations
10/28/20 Northland
Repare Therapeutics initiated with an Outperform at Northland
BMY Bristol-Myers
$59.25 /

-1.5 (-2.47%)

02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
01/20/21 Citi
Citi opens 'negative Catalyst Watch' on Bristol-Myers
RPTX Repare Therapeutics
$27.36 /

-4.31 (-13.61%)

BMY Bristol-Myers
$59.25 /

-1.5 (-2.47%)

  • 19
    Jun
BMY Bristol-Myers
$59.25 /

-1.5 (-2.47%)

BMY Bristol-Myers
$59.25 /

-1.5 (-2.47%)

BMY Bristol-Myers
$59.25 /

-1.5 (-2.47%)

Periodicals
Microsoft president Smith to testify at 'Big Tech' antitrust hearing, Axios says » 14:05
03/04/21
03/04
14:05
03/04/21
14:05
MSFT

Microsoft

$225.59 /

-2.03 (-0.89%)

, AMZN

Amazon.com

$2,969.00 /

-39.2 (-1.30%)

, AAPL

Apple

$119.56 /

-2.51 (-2.06%)

, GOOG

Alphabet

$2,034.80 /

+8.81 (+0.43%)

, FB

Facebook

$255.86 /

+0.52 (+0.20%)

The House Judiciary…

The House Judiciary antitrust subcommittee will be holding hearings this spring on antitrust issues and "Big Tech," as a follow up to the inquiries the government started a last year, wrote Ashley Gold for Axios. According to Axios, the Microsoft (MSFT) president Brad Smith, a proponent of anti- trust measures for "Big Tech" companies, will be testifying "before a House antitrust subcommittee hearing next Friday on the Big Tech antitrust issue and the media, added Axios. The Fly notes that the companies usually associated with "Big Tech" include Amazon (AMZN), Apple (AAPL), Google (GOOG), Facebook (FB) and Microsoft. Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$225.59 /

-2.03 (-0.89%)

GOOG Alphabet
$2,034.80 /

+8.81 (+0.43%)

FB Facebook
$255.86 /

+0.52 (+0.20%)

AMZN Amazon.com
$2,969.00 /

-39.2 (-1.30%)

AAPL Apple
$119.56 /

-2.51 (-2.06%)

MSFT Microsoft
$225.59 /

-2.03 (-0.89%)

03/03/21 Citi
Microsoft assumed with a Buy at Citi
02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
AMZN Amazon.com
$2,969.00 /

-39.2 (-1.30%)

03/03/21 Jefferies
Google Cloud traction under Kurian 'under-appreciated,' says Jefferies
02/26/21 B. Riley Securities
Plug Power recent selloff provides relative discount, says B. Riley
02/17/21 Needham
Kornit Digital price target raised to $125 from $76 at Needham
02/17/21 Morgan Stanley
Roku price target raised to $275 from $200 at Morgan Stanley
AAPL Apple
$119.56 /

-2.51 (-2.06%)

03/01/21 Wedbush
Asia checks bullish for Apple iPhone 12 builds, says Wedbush
03/01/21 JPMorgan
Broadcom won new new wireless charging chipset in iPhone 13, says JPMorgan
02/25/21 JPMorgan
JPMorgan 'tweaks' EPS estimate for Apple after cut to iPhone forecasts
02/24/21 Piper Sandler
Piper sees Apple developing 'full-blown' branded electric vehicle
GOOG Alphabet
$2,034.80 /

+8.81 (+0.43%)

02/12/21 Citi
Citi boosts Alphabet target but shares no longer a top pick
02/08/21 Stephens
Global Payments merchant business advanced by Google pact, says Stephens
FB Facebook
$255.86 /

+0.52 (+0.20%)

02/26/21 Jefferies
Twitter price target raised to $79 from $64 at Jefferies
02/16/21 Loop Capital
Facebook price target raised to $370 from $330 at Loop Capital
02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
MSFT Microsoft
$225.59 /

-2.03 (-0.89%)

GOOG Alphabet
$2,034.80 /

+8.81 (+0.43%)

FB Facebook
$255.86 /

+0.52 (+0.20%)

AMZN Amazon.com
$2,969.00 /

-39.2 (-1.30%)

AAPL Apple
$119.56 /

-2.51 (-2.06%)

MSFT Microsoft
$225.59 /

-2.03 (-0.89%)

GOOG Alphabet
$2,034.80 /

+8.81 (+0.43%)

FB Facebook
$255.86 /

+0.52 (+0.20%)

AMZN Amazon.com
$2,969.00 /

-39.2 (-1.30%)

AAPL Apple
$119.56 /

-2.51 (-2.06%)

MSFT Microsoft
$225.59 /

-2.03 (-0.89%)

GOOG Alphabet
$2,034.80 /

+8.81 (+0.43%)

FB Facebook
$255.86 /

+0.52 (+0.20%)

AMZN Amazon.com
$2,969.00 /

-39.2 (-1.30%)

AAPL Apple
$119.56 /

-2.51 (-2.06%)

MSFT Microsoft
$225.59 /

-2.03 (-0.89%)

GOOG Alphabet
$2,034.80 /

+8.81 (+0.43%)

FB Facebook
$255.86 /

+0.52 (+0.20%)

AMZN Amazon.com
$2,969.00 /

-39.2 (-1.30%)

AAPL Apple
$119.56 /

-2.51 (-2.06%)

On The Fly
Fly Intel: What to watch in Slack earnings report » 11:16
03/04/21
03/04
11:16
03/04/21
11:16
WORK

Slack Technologies

$40.27 /

+0.04 (+0.10%)

, CRM

Salesforce

$206.70 /

+0.63 (+0.31%)

, MSFT

Microsoft

$231.09 /

+3.47 (+1.52%)

Slack Technologies (WORK)…

ShowHide Related Items >><<
WORK Slack Technologies
$40.27 /

+0.04 (+0.10%)

MSFT Microsoft
$231.09 /

+3.47 (+1.52%)

CRM Salesforce
$206.70 /

+0.63 (+0.31%)

WORK Slack Technologies
$40.27 /

+0.04 (+0.10%)

12/09/20 Morgan Stanley
Salesforce $50B revenue target unlikely a source of upside, says Morgan Stanley
12/09/20 Canaccord
Salesforce valuation compelling especially on pullback, says Canaccord
12/09/20 Morgan Stanley
Slack Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
12/03/20 Wedbush
Slack Technologies upgraded to Neutral from Underperform at Wedbush
CRM Salesforce
$206.70 /

+0.63 (+0.31%)

02/26/21 Macquarie
Salesforce price target raised to $273 from $252 at Macquarie
02/23/21 Cowen
Salesforce survey points to a strong quarter, says Cowen
02/17/21 Mizuho
Salesforce price target raised to $290 from $275 at Mizuho
01/25/21
Fly Intel: Top five analyst upgrades
MSFT Microsoft
$231.09 /

+3.47 (+1.52%)

03/03/21 Citi
Microsoft assumed with a Buy at Citi
02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
WORK Slack Technologies
$40.27 /

+0.04 (+0.10%)

MSFT Microsoft
$231.09 /

+3.47 (+1.52%)

CRM Salesforce
$206.70 /

+0.63 (+0.31%)

WORK Slack Technologies
$40.27 /

+0.04 (+0.10%)

MSFT Microsoft
$231.09 /

+3.47 (+1.52%)

CRM Salesforce
$206.70 /

+0.63 (+0.31%)

WORK Slack Technologies
$40.27 /

+0.04 (+0.10%)

MSFT Microsoft
$231.09 /

+3.47 (+1.52%)

CRM Salesforce
$206.70 /

+0.63 (+0.31%)

WORK Slack Technologies
$40.27 /

+0.04 (+0.10%)

MSFT Microsoft
$231.09 /

+3.47 (+1.52%)

CRM Salesforce
$206.70 /

+0.63 (+0.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.